The Economic Burden of KCNT1-Related Disorders in the United States: Insights from Caregiver-Reported and EMR-Derived Data

This study quantifies the substantial economic burden of KCNT1-related disorders in the United States by combining caregiver-reported and electronic medical record data, revealing that annual costs per family range from approximately $355,000 to nearly $800,000 and are driven primarily by hospitalizations and caregiving-related income loss, thereby underscoring the urgent need for targeted therapies and systemic policy support.

The Gist

Imagine a family trying to navigate a stormy sea. For most people, the boat is sturdy, the waves are manageable, and the map is clear. But for families dealing with KCNT1-related disorders, they are sailing a tiny, fragile raft through a hurricane. The "KCNT1" gene is like a broken switch in the brain's electrical system, causing severe, uncontrollable seizures and developmental challenges that don't respond well to standard medicine.

This paper is like a financial weather report for those families. It asks two questions: "How much does this storm cost to survive?" and "Where is the money actually going?"

To answer this, the researchers used two different flashlights to look into the dark:

1. The "Caregiver Flashlight" (The Real-World View)

The researchers asked 34 parents (caregivers) to fill out a survey. Think of this as asking the people actually holding the oars to describe the storm.

• The Findings: The cost is astronomical. The study estimated that for just one year, a family might spend anywhere from $355,000 to nearly $800,000.
• The Analogy: Imagine if your annual grocery bill suddenly became the price of a luxury mansion. That's the scale we are talking about.
• Where the money goes: It's not just doctor bills. It's lost wages because a parent has to quit their job to be a full-time nurse, special wheelchairs, home modifications, and therapies.
• The Human Cost: More than half the families said they were in "financial hardship." Some even had to choose between paying for medicine and buying groceries. 12% of families had to delay medical care simply because they couldn't afford it.

2. The "EMR Flashlight" (The Hospital's View)

The researchers also looked at 49 patient records from a massive medical database. This is like looking at the hospital's receipt book.

• The Findings: This data only counted what the hospital billed for (direct medical costs). It showed that the first year of life is the most expensive, averaging about $154,000.
• The Trend: The storm is fiercest right at the beginning. In the first year, the baby is hospitalized often, tested constantly, and given many medications. After age two, the frequency of hospital visits drops, and the costs stabilize, but they never go away.
• The Missing Pieces: This receipt book didn't show the lost wages, the special food, or the time parents spent fighting insurance companies. It was a "partial bill."

The Big Picture: Why the Two Flashlights Don't Match

When you compare the two flashlights, you see a huge gap.

• The Hospital Receipt says: "It costs about $154k."
• The Parent's Wallet says: "It costs us nearly $800k."

Why? Because the hospital receipt doesn't count the "invisible costs." It doesn't count the parent who stopped working, the family that had to move to be near a specialist, or the money spent on special diets and equipment that insurance won't cover. The parent's view is the true total cost of the storm.

The Takeaway

This paper is a loud siren warning us that the current system is breaking these families.

• The Diagnosis: The disease is rare and severe, like a unique, complex puzzle that standard medicine hasn't solved yet.
• The Cost: It is financially devastating, far exceeding the cost of almost any other rare disease.
• The Solution Needed: We need faster cures (new drugs), better insurance rules, and government support. Without these, families are left trying to bail water out of a sinking boat with a teaspoon.

In short, this study proves that for families with KCNT1 disorders, the financial burden is a second, invisible disease that runs parallel to the medical one, and it needs to be treated with the same urgency.

Technical Summary

1. Problem Statement

KCNT1-related disorders are rare, severe neurogenetic conditions caused by pathogenic variants in the KCNT1 gene, leading to hyperactive neuronal firing, early-onset treatment-resistant epilepsy (e.g., EIMFS, EIDEE), and significant developmental comorbidities.

• Clinical Gap: There are currently no disease-modifying therapeutics; management is limited to symptom control, requiring lifelong, complex multidisciplinary care.
• Economic Gap: While rare diseases generally impose high costs, specific data quantifying the total economic burden (direct, indirect, and out-of-pocket) of KCNT1 disorders in the U.S. is sparse. Existing data often fails to capture the full scope of family financial strain, including lost productivity and non-medical expenses, which are critical for drug development justification and healthcare policy reform.

2. Methodology

The study employed a retrospective cohort analysis utilizing two complementary data sources to triangulate the economic burden:

A. Caregiver-Reported Survey (Qualitative & Quantitative Estimation)

• Cohort: 34 U.S.-based primary caregivers recruited from the KCNT1 Epilepsy Foundation registry (March–April 2025).
• Instrument: A structured survey capturing insurance status, medical/non-medical expenses, and indirect costs.
• Data Collection Strategy: Due to the difficulty of tracking exact figures for rare, complex conditions, respondents estimated annual costs using predefined cost brackets (ranging from $0 to >$250,000) across four categories:
  1. Direct Medical Costs (appointments, hospitalizations, meds).
  2. Indirect Medical Costs (productivity loss, unpaid caregiving labor).
  3. Non-Medical Costs (nutritional support, home modifications, special equipment).
  4. Non-Covered Costs (out-of-pocket expenses not reimbursed by insurance).
• Analysis: Costs were aggregated using lower and upper bounds of the selected brackets to generate a range of total annual expenses.

B. Electronic Medical Record (EMR) Analysis (Objective Clinical Data)

• Cohort: 49 U.S.-based patients with confirmed KCNT1 variants from the Citizen Health database.
• Inclusion Criteria: Analysis was restricted to patients ≤6 years of age to ensure data completeness (older records were deemed incomplete due to mortality or loss to follow-up).
• Data Extraction: Clinical services were mapped to CPT and HCPCS codes.
• Cost Modeling:
  • Diagnostic/Therapeutic Procedures: Priced using the CMS Physician Fee Schedule.
  • Durable Medical Equipment (DME): Priced via the DME Coding System (Palmetto GBA).
  • Medications: Priced using GoodRx data.
  • Hospitalizations: Estimated using 2022 Kaiser Family Foundation data, specifically utilizing Nebraska's median per-diem rate ($2,879) as a national proxy to standardize regional variations.
• Limitation: This dataset captured only direct medical costs and did not include indirect or non-medical expenses.

3. Key Results

A. Caregiver-Reported Findings (n=34 survey respondents; n=11 provided cost estimates)

• Financial Hardship: 53% (18/34) of caregivers reported financial hardship. 12% (4/34) admitted to delaying or avoiding medical care due to cost.
• Cost Breakdown:
  • Direct Medical Costs: The highest reported category, driven by hospitalizations, medications, and therapies.
  • Indirect Costs: Informal caregiving (lost wages/productivity) was the largest component of indirect costs.
  • Non-Medical Costs: Significant expenditures on nutritional support, special equipment, and home modifications.
• Total Annual Cost Estimates (n=11):
  • Mean Range: $355,474 (lower bound) to $797,727 (upper bound) per family per year.
  • Median Range: $265,018 to $620,000.
  • Context: These figures vastly exceed the 2023 U.S. average per-person health spending ($14,570) and the average rare disease cost ($62,084).

B. EMR-Derived Findings (n=49 patients)

• Utilization Patterns: Healthcare utilization peaked in the first year of life (diagnostics, hospitalizations, prescriptions) and declined by >50% in the second year, stabilizing thereafter. Therapeutic procedures remained consistent across ages.
• Cost Drivers:
  • Hospitalizations were the single largest cost contributor across all ages.
  • First-Year Costs: The average total direct medical cost in the first year of life was $154,389 (SD = $117,716; Median = $131,997).
  • Trend: Costs dropped significantly after age 2 as acute hospitalization needs decreased, though device usage (e.g., wheelchairs, orthotics) increased in years 2–3.

4. Key Contributions

1. First Comprehensive U.S. Cost Analysis: This is the first study to quantify both medical and non-medical costs for KCNT1-related disorders using a dual-source approach (caregiver survey + EMR).
2. Revealing the "Hidden" Burden: By comparing EMR data ($154k first-year direct cost) with caregiver data ($355k–$797k total annual cost), the study demonstrates that EMR data alone significantly underestimates the true economic impact, missing critical indirect and non-medical costs.
3. Policy and Development Evidence: The data provides concrete economic justification for:
   • Drug Development: Supporting Investigational New Drug (IND) applications by quantifying the unmet need and potential cost savings of disease-modifying therapies.
   • Insurance Reform: Highlighting gaps in coverage that lead to treatment delays and financial distress.
   • Legislative Action: Advocating for support systems for families managing high-burden rare diseases.

5. Significance and Limitations

• Significance: The study underscores the urgent need for rapid diagnostics, targeted therapies, and systemic healthcare support. It establishes a baseline for future health economic evaluations and highlights that the economic burden is not just medical but extends to the entire family's socioeconomic stability.
• Limitations:
  • Sample Size: Small cohort for caregiver cost estimates (n=11) limits statistical generalizability.
  • Data Granularity: Caregiver data relied on brackets (introducing estimation uncertainty) and lacked specific demographic/genotypic correlations.
  • EMR Constraints: EMR data was limited to children ≤6 years and excluded indirect/non-medical costs.
  • Geographic Specificity: Findings are specific to the U.S. fragmented insurance system and may not apply to countries with universal coverage.
  • Cost Modeling: Using Nebraska hospital rates as a national average may underestimate costs in major urban pediatric centers.

Conclusion: KCNT1-related disorders impose a catastrophic economic burden on U.S. families, with total annual costs reaching nearly $800,000 in high-impact scenarios. The disparity between direct medical costs and total family costs necessitates a holistic approach to care funding and drug development investment.